Shire has received approval from the European Medicines Agency’s (EMA) for the production of VPRIV (velaglucerase alfa) at its new manufacturing facility in Lexington, MA. The company also has an EMA approved facility in Cambridge, MA, for the manufacture of VPRIV drug substance. This additional capacity allows the company to significantly increase global supply of VPRIV and provides additional manufacturing flexibility. The new facility increases bioreactor capacity from 1000 to 8000L, an...